Market Overview

UPDATE: Morgan Stanley Upgrades AbbVie


In a note released Wednesday, Morgan Stanley analyst David Risinger upgraded AbbVie (NYSE: ABBV) from Equal-weight to Overweight and raised the price target from $47 to $60.

Risinger made it clear that the primary reason for this upgrade is AbbVie's hepatitis-C cure regimen which is set to launch in late 2014. With the launch of the hepatitis-C cure, Risinger expects AbbVie will be able to capture a larger portion of the available market (over 33 percent) in 2015. Based on this Risinger has significantly raised his EPS estimates for 2014 - 2016 to a level "well above consensus".

For 2014 he increased his estimate four percent from $3.12 to $3.23 ($3.13 consensus) , 37 percent for 2015 from $3.60 to $4.82 ($3.72 consensus) and 30 percent for 2016 from $3.83 to $4.98 ($4.23 consensus).

Latest Ratings for ABBV

Aug 2019UpgradesNeutralOverweight
Jun 2019UpgradesMarket PerformOutperform
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color News Upgrades Price Target Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!

Latest Ratings

HUBBInitiates Coverage On160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Brean Capital Reiterates On DirecTV On Good Market Position

UPDATE: Brean Capital Reiterates On Activision Blizzard On 2H14 Upside Potential